Alkermes
NEWS
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
The U.S. Food and Drug Administration issued a warning letter to the company for misbranding its opioid addiction medication Vivitrol in promotional materials.
Proteros biostructures GmbH announced that Rodin Therapeutics, Inc., a Boston, MA based biotech company developing novel, small molecule therapeutics for synaptopathies has been acquired by Alkermes plc, a global biopharmaceutical company headquartered in Dublin, Ireland.
Under the terms of the deal, Alkermes is paying $100 million in cash upfront. Rodin will be eligible for future payments of up to $850 million based on clinical and regulatory milestones and sales thresholds.
The approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway.
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
Biogen and Alkermes announced positive topline data from EVOLVE-MS-2, a Phase III trial of diroximel fumarate for relapsing-remitting multiple sclerosis compared to Tecfidera.
Pharma and biotech companies from Asia to Europe provide updates on business and clinical activities.
As drugmakers continue to develop an understanding of what pain is to the human body, it helps drive the development of innovative manners to treat it that transcend addictive options such as opioids.
JOBS
IN THE PRESS